| INTRODUCTION
Twentieth century witnessed significant changes in the socioeconomic parameters that define the role of women in the society. In 1900, <20% of women participated in the labor force in the United States.
This number increased to 33% by 1950 and 60% by 2000.
In parallel with women's increasing participation in the workforce and realization that college education increases employment and earning potential, college graduation rate that was less than 4% for women in the United States in 1940 reached 32.5% in 2015, equaling that of men. These changes made a significant impact on women's decision regarding the timing of childbearing, and the number of women delivering their first child after the age of 35 increased from 1/100 in 1970 to 1/12 in 2006. 1 However, delaying childbearing was not consequences as reflected by the data provided by the Society of Assisted Reproductive Technology (SART) regarding women undergoing infertility treatment in the United States. Indeed, despite a steady increase in human longevity over the past centuries, culminating in a life expectancy at birth that is longer than 80 years for women in the United States, age of menopause remained essentially unchanged at approximately 50, and scientific research failed to impact upon ovarian aging.
2,3
Within the context of assisted reproduction, ovarian aging commonly refers to the declining potential of ovaries to produce oocytes in adequate number or quality in response to controlled ovarian stimulation. 4 Patients who present with ovarian aging are commonly di- There are several potential molecular mechanisms contributing to ovarian aging, including impaired DNA repair, 6 telomere shortening, 7 metabolic/energetic disorders, and mitochondrial dysfunction.
Understanding the mechanisms of reproductive senescence and developing strategies to prevent or delay ovarian aging would have significant medical and social implications. In this review, we will summarize data related to the association of mitochondrial dysfunction with ovarian aging.
| MITOCHONDRIA: STRUCTURE AND FUNCTION
Mitochondria are double-membrane-bound organelles that are ubiquitously present in the cytoplasm of eukaryotic cells and generate most of the energy of the cell in the form of adenosine triphosphate (ATP). In addition to supplying cellular energy, mitochondria are involved in other cellular activities, such as calcium homeostasis and substrate oxidation, and play a key role in the regulation of cell cycle, differentiation, senescence, and death. The mitochondrial free radical theory of aging proposes that the high levels of free radicals and ROS within mitochondria may result in mtDNA mutations leading to loss of synchrony in the production on functional ETC. proteins by mtDNA and nuclear DNA, which results in partial uncoupling of the respiratory chain. 13, 14 Indeed, due to the close proximity of mtDNA to ETC., its lack of protective histones, and limited repair mechanisms, the mutation rate of mtDNA is almost 25 times higher than that of nuclear DNA. 15 The proposed model further suggests that increased mtDNA mutations would cause further accumulation of ROS and increased mtDNA mutations. This cycle could result in an exponential increase in mtDNA mutation burden, which could range from ATP reduction up to cell cycle arrest or even apoptosis. Indeed, increased ROS levels, accumulated mtDNA mutations, and a decline in mitochondrial function have been reported in aging. Also consistent with this theory, mouse models that are prone to mtDNA mutations due to a PolgA (the nucleus-encoded catalytic subunit of mtDNA polymerase) deficient in proof-reading function, are associated with accumulated mtDNA mutations and a premature aging phenotype, leading to both male and female infertility. 16 Recent studies showed that maternally inherited mtDNA mutations alone or in combination with somatic mtDNA mutation may induce the aging phenotype and reduce the life span in mice, and that the reduced fertility caused by mtDNA mutations in the maternal germline could be reversed by the introduction of normal mtDNA. 17, 18 These findings demonstrate that experimental introduction of mtDNA mutations in animal models results in aging in general and ovarian aging in particular. However, recent studies show that mtDNA mutation burden associated with human aging is very low, 19 and biopsies of embryos for women over 40 years old do not show an increase in mtDNA mutations. 20 These observations strongly suggest that a model based on
MFRTA is an oversimplification and fails to explain the mechanism of ovarian senescence and overall human aging. 
| GENES IMPORTANT FOR MITOCHONDRIAL FUNCTION
Mitochondrial diseases are mostly caused by mutations in nuclear DNA and in some cases (about 15%) in mtDNA, which affect mitochondrial function. 30 Several reports based on the use of transgenic methods have revealed a key role for specific genes in mitochondrial diseases. [31] [32] [33] [34] [35] [36] Regulation of mtDNA gene expression is extremely important for modulating the OXPHOS capacity in response to metabolic requirements and in stress conditions.
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To ensure proper mitochondrial function, mtDNA genome must be replicated, transcribed, and translated accurately. All the components involved in mtDNA replication and transcription are encoded in the nuclear genome, and mutations of genes essential for mtDNA replication (POLγ and TWINKLE) and for transcription/translation (TFAM, TFB1M, mTERFs, POLRMT, LRPPRC, and DARS2) are all embryonic lethal except mTERF1. [34] [35] [36] [38] [39] [40] [41] [42] [43] [44] Mitochondria are dynamic organelles that are constantly undergoing fusion and fission to adapt to cellular energetic demands and maintain the mitochondrial function. A number of proteins belonging to the dynamin GTPase protein family are involved in mitochondrial fission and fusion. 45 To explore the implication of dynamic genes in mitochondrial function, several laboratories have investigated the impact of global genetic disruption of genes in mouse. The work from
Chen et al. 31 revealed that knockout of Mfn1 or Mfn2, which are responsible for mitochondrial fusion in mouse, results in embryonic lethality due to a severe developmental delay and placental defects.
OPA1, another gene involved in mitochondrial fusion, is targeted to the inner mitochondrial membrane. Homozygous deletion of OPA1
is also embryonic lethal with a block in development. 46 
| CLINICAL IMPLICATIONS FOR TESTING AND TREATMENT

| mtDNA copy number as a predictor of embryo viability
There seems to be a close relationship between mitochondrial dysfunction and the decline of oocyte quality and embryo developmental potential in human and in mammalian aging models.
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The number of mitochondria in mammalian cells ranges from a few hundred to thousands, with the highest number observed in mature oocytes at approximately 100 000. 76 As the mitochondria are inherited exclusively from the oocyte, and the replication of mtDNA only resumes at blastocyst stage after the differentiation of the inner cell mass and the trophectoderm, 77,78 the mtDNA copy number remains unchanged during cleavage stages and reflects the mtDNA content of the oocyte.
76,79-82
Recent studies suggest that elevated mtDNA copy number is associated with decreased implantation potential in human IVF embryos.
Fragouli et al. 75 assessed day 3 and day 5 embryos by using a combi-
nation of array-comparative genomic hybridization (aCGH), real-time quantitative PCR (RT-qPCR), and next-generation sequencing (NGS)
and found that a significantly higher mtDNA copy number was observed in embryos from older women. Additionally, mtDNA levels were elevated in aneuploid embryos (independent of age) compared to euploid ones and euploid blastocysts that failed to implant compared to those that implanted. Authors established a mtDNA quantity threshold, above which pregnancy did not occur. In a subsequent study, Diez-Juan et al. 83 found that a higher mtDNA copy number in euploid embryos is indicative of lower embryo viability and implantation for both blastocysts and cleavage-stage embryos. The abovementioned studies proposed that mtDNA copy number is an exciting new paradigm for embryo quality assessment. The importance of mitochondrial threshold in oocyte competence is also shown on many animal models including mouse, 84 pig, 85 and cattle. 52 
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Mitochondrial fusion Drp1 oocyte specific knockout mice: female infertility, defective for follicular maturation and ovulation, reduced ovulation activity. eliminating well-to-well variability has also been described. 90 It is likely that some of these more advanced approaches and/or NGS will be utilized in clinical settings in the future, where the impact of mtDNA copy number analysis on clinical outcomes will need to be established.
| Mitochondrial nutrients
As mitochondrial dysfunction is associated with ovarian aging and is and ALA is required for normal embryonic development in mice.
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CoQ10 is a lipid-soluble electron transporter, which transports electrons from complexes I and II to complex III in ETC. (Figure 1 ) and is critical for the stabilization of complex III. 94 CoQ10 is also involved in the transport of protons into the mitochondria to maintain the membrane potential and ATP production. 95 Several studies reported decreased levels of CoQ10 associated with tissue-specific senescence. 96, 97 In addition, supplementation of CoQ10 seems to restore mitochondrial function in the oocyte and delay ovarian aging in mice. [98] [99] [100] 
| Mitochondrial transfer
Two decades ago, transfer of cytoplasm from an oocyte obtained from a younger woman into the oocyte of an older woman was reported to improve oocyte competence and embryo development. 112 Subsequently, more than 50 successful live births have been achieved with this method. 113 However, due to lack of adequate experimental data and the potential risk associated with the transmission thirdparty genetic material, the US Food and Drug Administration (FDA)
suggested (in 2002) that donor cytoplasmic transfer should be suspended pending the outcome of further studies.
As oocyte cytoplasm has numerous components with yet unknown functions, mitochondrial replacement has been proposed as an alternative. Indeed, transfer of isolated mitochondria is sufficient to improve mitochondrial function and reproduction in the mouse. 114 Spindle chromosome transfer or pronuclear transfer (PNT) of oocytes has also been proposed as potential treatments for human diseases caused by mtDNA mutations. 115, 116 However, these approaches received a significant amount of criticism worldwide due to the risk of heteroplasmy and potential long-term health consequences in the offspring. 117, 118 Indeed, studies in mice showed that heteroplasmy is associated with cognitive abnormalities 119 and a phenotype resembling early-onset metabolic syndrome. 120 Nevertheless, mitochondrial transfer from a donor has recently been approved for use in humans in the UK for the treatment of carriers of severe mitochondrial disorders (February 3, 2015) .
In the setting of age-related infertility, autologous transfer of mitochondria from somatic cells has been proposed to avoid risks associated with heteroplasmy. This method utilizes mitochondria obtained from the ovarian germline cells to eliminate the tissue-specific differences that could potentially affect embryonic development.
121,122
Autologous germline mitochondrial energy transfer (AUGMENT) has recently been commercialized. Using this technology, a prospective cohort study with historical controls by Fakih et al. reported an approximately eightfold to 10-fold increase in clinical pregnancy rates in a selected group of women with very poor IVF outcomes in the past. 123 A subsequent study using the same technology also reported a significant improvement in fertilization rates. 124 While the initial studies showed significant improvement compared to the outcomes of the same women in the past, they failed to achieve pregnancy in older women, and the true efficacy of this approach remains to be established in well-designed clinical studies without selection bias.
| SUMMARY AND CONCLUSIONS
Mitochondria play a number of key roles in cellular physiology and have been strongly implicated in aging through a number of mechanisms. Within the context of reproduction, mtDNA copy number may constitute a test for the prediction of embryo viability, increasing the predictive efficacy of preimplantation genetic screening (PGS). In addition, nutrients improving mitochondrial function and replacement of functional mitochondria into the germ cells may be used in the clinical setting as a potential treatment for ovarian aging. All these exciting clinical applications will need to be validated for safety and efficacy.
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